GlassScriptPhysician profile
Nicolette Hampton
NPI 1184083818
$1,822.62
in general payments reported to CMS, 2019-2025
24 companies · $430 in 2025
The $430 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $300 · 2022: $410 · 2023: $414 · 2024: $269 · 2025: $430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,112.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $577.58 | 2021-2025 | |
| Astellas Pharma US INC | $252.26 | 2021-2025 | Veozah |
| Amgen INC. | $180.88 | 2021-2025 | Evenity, Prolia, Prolia |
| Grifols USA, LLC | $126.76 | 2021-2023 | Prolastin-C Liquid |
| Novo Nordisk INC | $97.87 | 2021-2025 | Rybelsus, Ozempic |
| Xeris Pharmaceuticals, INC. | $82.46 | 2021-2023 | Gvoke Hypopen |
| Lilly USA, LLC | $56.60 | 2021-2025 | Mounjaro, Zepbound |
| Vanda Pharmaceuticals INC. | $51.33 | 2024-2025 | Fanapt |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.02 | 2021-2023 | Synjardy, Jardiance |
| Sumitomo Pharma America, INC. | $39.15 | 2024-2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $33.37 | 2023-2024 | Gardasil 9, Capvaxive, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $30.32 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.25 | 2021-2022 | |
| Pfizer INC. | $27.55 | 2024 | |
| Inspire Medical Systems, INC. | $25.85 | 2025 | Inspire |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $25.39 | 2022-2023 | Minimed 780g |
| Boston Scientific Corporation | $23.41 | 2025 | Watchman Access System |
| Abbott Laboratories | $19.92 | 2022 | |
| Galderma Laboratories, L.P. | $18.94 | 2025 | Dysport |
| Teva Pharmaceuticals USA, INC. | $18.64 | 2022 | |
| Organon LLC | $17.24 | 2021 | |
| Roche Diagnostics Corporation | $15.28 | 2021 | |
| Glaxosmithkline, LLC. | $13.93 | 2024 | Arexvy, Shingrix, Bexsero |
| E.R. Squibb & Sons, L.L.C. | $13.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicolette Hampton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.